Align Technology (ALGN)
(Delayed Data from NSDQ)
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Haemonetics Banks on Solid Plasma & Haemonetics Management
by Zacks Equity Research
Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).
Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4
by Zacks Equity Research
Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.
Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.
Focus on These 5 Top-Ranked Profitable Stocks in August
by Zacks Equity Research
Higher net income ratio usually implies a company's ability to generate ample revenue and successfully manage all its business functions.
STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up
by Zacks Equity Research
STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.
BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates
by Zacks Equity Research
BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.
Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.
CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed
by Zacks Equity Research
CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.
Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact
by Zacks Equity Research
Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.
Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.
Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.
Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines
by Zacks Equity Research
Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.
Cardiovascular Systems Rides on Innovation Amid Several Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.
Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.
Wright Medical Group (WMGI) Q2 Loss Narrower than Expected
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.
Illumina (ILMN) Rides on New Products, Low Margin a Concern
by Zacks Equity Research
Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.
Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.
Bull of the Day: Align Technology (ALGN)
by Kevin Cook
The clear winner in alternative dental alignment continues to make long-term investors smile
Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance
by Zacks Equity Research
Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.
Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top
by Zacks Equity Research
Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.
Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2
by Zacks Equity Research
Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.
Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.